Genzyme, a Sanofi company, announced today a phase 1 study, called NEO1, to investigate a second generation product for Pompe disease in humans. The study is planned to be conducted at multiple sites in the United States and throughout Europe. This study will last up to 41 weeks and approximately 21 patients will participate in the study.
Read more
- Update on Genzyme’s neoGAA Program, July 16, 2013 (Download PDF, 0.2 MB)
- NEO1 Clinical Study on ClinicalTrials.gov (External Link)
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.